nAMD | BayerPRO Ireland

This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Neovascular age-related macular degeneration (nAMD)

EYLEA^® 8mg (aflibercept 114.3 mg/ml) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).

For those who want flexibity to optimise patient intervals to Q16 and beyond

Save sight

whilst minimising treatment burden

Flexibility to extend treatment

intervals as far as Q24

Suppress VEGF

with a safety profile comparable to EYLEA 2mg

With only 3 loading doses and as few as 8 injections over 2 years
^‡§

^{* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.}
^{† Extend treatment intervals across your nAMD clinic, as far as Q24, for your eligible nAMD patients.}
^{‡ Patients could receive as few as 8 injections per dosing schedule within the trial protocol.}
^{§ Loading doses refers to the initial monthly dosing phase.}

PULSAR

Optimise vision whilst minimising burden

Primary endpoint: mean change in BCVA from baseline to Week 48

With EYLEA 8mg, patients achieved lasting BCVA gains from baseline with as few as 5 injections in Year 1^*

EYLEA 8mg was non-inferior vs. EYLEA 2mg

^{* Includes 3 initial monthly doses.}

Week 48

Flexibility to extend treatment intervals for eligible nAMD patients

In PULSAR, ~8 out of 10 patients maintained 16-week treatment intervals from baseline through Week 48^*

^{*Patients completing Week 48: 2Q8 n=309; 8Q12 n=316; 8Q16 n=312.}

Week 96

Extend treatment intervals for eligible patients across your nAMD clinic

In PULSAR, ~8 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 96^*

^{*Patients completing Week 96: 8Q12 n=291; 8Q16 n=292.}

Extend treatment intervals beyond expectations

The first and only anti-VEGF for nAMD that allows for extension to treatment intervals of Q24 after reaching Q16^*

^{* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.}
^{† Patients completing Week 96: 8Q12 n=291; 8Q16 n=292.}

See how you could optimise your DME patient's treatment journey and your clinic's capacity with EYLEA 8mg

Dosing

Discover proactive dosing in nAMD and DME

Mechanism of Action (MoA)

Discover more about the MoA of EYLEA 8mg

Abbreviations

2Q8

^{, 2 mg every 8 weeks;}^8Q12^{, 8 mg every 12 weeks;}^8Q16^{, 8 mg every 16 weeks;}^BCVA^{, best-corrected visual acuity;}^CI^{, confidence interval;}^CRT^{, central retinal thickness;}^CST^{, central subfield thickness;}^DME^{, diabetic macular oedema;}^DRM^{, dose regimen modification;}^ETDRS^{, Early Treatment of Diabetic Retinopathy Study;}^FAS^{, full analysis set;}^ICE^{, intercurrent event;}^IRF^{, intraretinal fluid;}^LOCF^{, last observation carried forward;}^LS^{, least squares;}^MMRM^{, mixed model for repeated measurements;}^MoA^{, mechanism of action;}^nAMD^{, neovascular (wet) agerelated macular degeneration;}^Q8^{, every 8 weeks;}^Q16^{, every 16 weeks;}^Q24^{, every 24 weeks;}^SD^{, standard deviation;}^SmPC^{, Summary of Product Characteristics;}^SRF^{, subretinal fluid;}^T&E^{, treat and extend;}^VEGF^{, vascular endothelial growth factor.}

PP-EYL_8mg-IE-0151-1 | December 2025

References

1
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
2
Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
3
Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4
Brown DM. Aflibercept 8 mg in patients with nAMD: 48-week results from the phase 3 PULSAR trial. Angiogenesis, exudation, and degeneration 2023. 10–11 February 2023. Virtual. Oral presentation.
5
ClinicalTrials.gov. NCT04423718. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04423718. Accessed: December 2025.